Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits
Potential for New Approach to the Treatment and Prevention of
Breast Cancer
THE WOODLANDS, Texas--(BUSINESS WIRE)--Jul 5, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) today announced that an articlehas been published in the July 1, 2007 issue of Oncology Reportsindicating a potential for a new approach to the treatment ofbreast cancer using P
roellex. The article reviews the findings froma study conducted in an accepted in vivo rat model of breastcancer. The study...
Repros Reports That Proellex Has Demonstrated Superior Efficacy and
Safety in Endometriosis When Compared to Standard of Drug Care
THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 11, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) today released top-line findingsfrom its six month study of P
roellex in the treatment ofendometriosis. This study, conducted in Europe, enrolled 39premenopausal women and has completed six months of dosing. Thestudy included three dose levels of P
roellex(TM) as well as apositive control arm. The po...
Repros' Proellex Shows Statistically Significant Improvement in
Primary Endpoint in Phase 2 Trial in the Treatment of Uterine
Fibroids
THE WOODLANDS, Texas--(BUSINESS WIRE)--Apr 3, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) announced final results of a U.S.Phase 2 study of P
roellex(TM), an oral drug being developed torelieve symptoms of uterine fibroids. This study suggests thattreatment with P
roellex results in a statistically highlysignificant improvement in symptoms associated with uterinefibroids and is generally w...